Galectin Therapeutics Inc. (GALT)

Oncology Corporate Profile

Stock Performance

2.3300
0.0000

HQ Location

4960 Peachtree Industrial Boulevard, Suite 240
Norcross, GA 30071

Company Description

Galectin Therapeutics (GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. They are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. They are pursuing a clear development pathway to clinical enhancement and commercialization for their lead compounds in liver fibrosis and cancer.

Website: http://www.galectintherapeutics.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
GM-MD-02 (+ ipilimumab)immunotherapyMelanomaI
GM-MD-02 (+ pembrolizumab)MelanomaI

View additional information on product candidates here »

Pipeline image

Source


http://www.galectintherapeutics.com

Recent News Headlines

Galectin Therapeutics Issues Statement Regarding GALTW and GALTU

3/23/2017 12:03 pm

[GlobeNewswire] - NORCROSS, Ga., March 23, 2017-- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, announced today that trading will be halted in GALTW and GALTU at close ...

Galectin Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

3/21/2017 12:03 pm

[GlobeNewswire] - NORCROSS, Ga., March 21, 2017-- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, announced today that the Company will release fourth quarter and full year ...

Galectin Therapeutics and Aratana Therapeutics Look Forward to the 4th Quarter of 2017

3/15/2017 01:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 15, 2017 / The development of a drug and receiving a passing grade from the FDA is not always enough to keep a company financially solvent. Investors are required to be ...

GR-MD-02 Demonstrates Clinically Significant Effect in Patients with Severe and Refractory Atopic Dermatitis (Eczema)

3/14/2017 12:04 pm

[GlobeNewswire] - NORCROSS, Ga., March 14, 2017-- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, today announced preliminary results for severe and refractory atopic dermatitis ...

Galectin Therapeutics to Present at 29th Annual ROTH Conference

3/9/2017 01:03 pm

[GlobeNewswire] - NORCROSS, Ga., March 09, 2017-- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.D., the Company's chief operating ...

Galectin’s GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis

3/6/2017 01:03 pm

[GlobeNewswire] - Research done in partnership with San Antonio Military Medical Center showed an average 50% PASI reduction by end of 24- week treatment period. NORCROSS, Ga., March 06, 2017-- Galectin Therapeutics Inc., ...

Bull Market Ahead for the Biotech Industry in 2017? Today's Reports on Sarepta Therapeutics and Galectin Therapeutics

2/22/2017 02:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 22, 2017 / The Biotech Industry's rally does not appear to be losing any steam in 2017. Both the iShares NASDAQ Biotechnology Index ETF and the SPDR S&P Biotech ETF ...

Galectin Therapeutics to Present at BIO CEO & Investor Conference

2/8/2017 01:03 pm

[GlobeNewswire] - NORCROSS, Ga., Feb. 08, 2017-- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.D., the Company’ s chief operating ...

Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials

2/7/2017 09:04 pm

[GlobeNewswire] - NORCROSS, Ga., Feb. 07, 2017-- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, and the Providence Cancer Center today announced the presentation of preclinical ...

Galectin Therapeutics Presentation Now Available for On-Demand Viewing

2/6/2017 01:03 pm

[PR Newswire] - NORCROSS, Ga., Feb. 6, 2017 /PRNewswire/ -- Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, today announced that the February 2nd presentation from Peter G. Traber, M.D, President, Chief Executive Officer, and Chief Medical Officer, is now available for on-demand viewing at VirtualInvestorConferences.com. Galectin Therapeutic Inc.'s presentation will be available 24/7 for 90 days.

Galectin Therapeutics Presentation Now Available for On-Demand Viewing

2/6/2017 01:03 pm

[CNW Group] - Galectin Therapeutics Presentation Now Available for On-Demand Viewing

Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial

2/1/2017 01:01 pm

[GlobeNewswire] - NORCROSS, Ga., Feb. 01, 2017-- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, today announced it has generated sufficient financing to cover currently ...

Galectin Therapeutics to Webcast, Live, at VirtualInvestorConferences.com on February 2

1/30/2017 01:03 pm

[PR Newswire] - NORCROSS, Ga., Jan. 30, 2017 /PRNewswire/ -- Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D, president, chief executive officer and chief medical officer, will present live at VirtualInvestorConferences.com on February 2, 2017. This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

Galectin Therapeutics to Webcast, Live, at VirtualInvestorConferences.com on February 2

1/30/2017 01:03 pm

[CNW Group] - Galectin Therapeutics to Webcast, Live, at VirtualInvestorConferences.com on February 2

Galectin Therapeutics Announces $4 Million in New Equity Financings

12/29/2016 02:01 pm

[at noodls] - NORCROSS, Ga., Dec. 29, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has recently completed ...

Galectin Therapeutics Announces $4 Million in New Equity Financings

12/29/2016 02:00 pm

[GlobeNewswire] - NORCROSS, Ga., Dec. 29, 2016-- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, today announced it has recently completed a private placement of its common ...